The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Heart and Lung Transplants from HCV-Infected Donors to Uninfected Recipients
Open accessAbstract
BACKGROUND: Hearts and lungs from donors with hepatitis C viremia are typically not transplanted. The advent of direct-acting antiviral agents to treat hepatitis C virus (HCV) infection has raised the possibility of substantially increasing the donor organ pool by enabling the transplantation of hearts and lungs from HCV-infected donors into recipients who do not have HCV infection. METHODS: We conducted a trial involving transplantation of hearts and lungs from donors who had hepatitis C viremia, irrespective of HCV genotype, to adults without HCV infection. Sofosbuvir-velpatasvir, a pangenotypic direct-acting antiviral regimen, was preemptively administered to the organ recipients for 4 weeks, beginning within a few hours after transplantation, to block viral replication. The primary outcome was a composite of a sustained virologic response at 12 weeks after completion of antiviral therapy for HCV infection and graft survival at 6 months after transplantation. RESULTS: A total of 44 patients were enrolled: 36 received lung transplants and 8 received heart transplants. The median viral load in the HCV-infected donors was 890,000 IU per milliliter (interquartile range, 276,000 to 4.63 million). The HCV genotypes were genotype 1 (in 61% of the donors), genotype 2 (in 17%), genotype 3 (in 17%), and indeterminate (in 5%). A total of 42 of 44 recipients (95%) had a detectable hepatitis C viral load immediately after transplantation, with a median of 1800 IU per milliliter (interquartile range, 800 to 6180). Of the first 35 patients enrolled who had completed 6 months of follow-up, all 35 patients (100%; exact 95% confidence interval, 90 to 100) were alive and had excellent graft function and an undetectable hepatitis C viral load at 6 months after transplantation; the viral load became undetectable by approximately 2 weeks after transplantation, and it subsequently remained undetectable in all patients. No treatment-related serious adverse events were identified. More cases of acute cellular rejection for which treatment was indicated occurred in the HCV-infected lung-transplant recipients than in a cohort of patients who received lung transplants from donors who did not have HCV infection. This difference was not significant after adjustment for possible confounders. CONCLUSIONS: In patients without HCV infection who received a heart or lung transplant from donors with hepatitis C viremia, treatment with an antiviral regimen for 4 weeks, initiated within a few hours after transplantation, prevented the establishment of HCV infection. (Funded by the Mendez National Institute of Transplantation Foundation and others; DONATE HCV ClinicalTrials.gov number, NCT03086044.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Optimal two-stage designs for phase II clinical trials.
Simon, R. (1989) · Controlled Clinical Trials · doi:10.1016/0197-2456(89)90015-9 · Cited by 3,636
Group sequential methods in the design and analysis of clinical trials
POCOCK, S. J. (1977) · Biometrika · doi:10.1093/biomet/64.2.191 · Cited by 1,831
Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection
Afdhal, N., Zeuzem, S., Kwo, P., Chojkier, M., Gitlin, N., Puoti, M., Romero-Gomez, M., Zarski, J.-P., Agarwal, K., Buggisch, P., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402454 · Cited by 1,705
Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection
Afdhal, N., Reddy, K. R., Nelson, D. R., Lawitz, E., Gordon, S. C., Schiff, E., Nahass, R., Ghalib, R., Gitlin, N., Herring, R., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1316366 · Cited by 1,307
Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection
Sulkowski, M. S., Gardiner, D. F., Rodriguez-Torres, M., Reddy, K. R., Hassanein, T., Jacobson, I., Lawitz, E., Lok, A. S., Hinestrosa, F., Thuluvath, P. J., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1306218 · Cited by 1,190
Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection
Feld, J. J., Jacobson, I. M., Hézode, C., Asselah, T., Ruane, P. J., Gruener, N., Abergel, A., Mangia, A., Lai, C.-L., Chan, H. L. Y., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1512610 · Cited by 1,106
Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect
Gao, M., Nettles, R. E., Belema, M., Snyder, L. B., Nguyen, V. N., Fridell, R. A., Serrano-Wu, M. H., Langley, D. R., Sun, J.-H., O’Boyle II, D. R., et al. (2010) · Nature · doi:10.1038/nature08960 · Cited by 939
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection
Foster, G. R., Afdhal, N., Roberts, S. K., Bräu, N., Gane, E. J., Pianko, S., Lawitz, E., Thompson, A., Shiffman, M. L., Cooper, C., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1512612 · Cited by 846
Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1
Wyles, D. L., Ruane, P. J., Sulkowski, M. S., Dieterich, D., Luetkemeyer, A., Morgan, T. R., Sherman, K. E., Dretler, R., Fishbein, D., Gathe, J. C., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503153 · Cited by 419
Trial of Transplantation of HCV-Infected Kidneys into Uninfected Recipients
Goldberg, D. S., Abt, P. L., Blumberg, E. A., Van Deerlin, V. M., Levine, M., Reddy, K. R., Bloom, R. D., Nazarian, S. M., Sawinski, D., Porrett, P., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1705221 · Cited by 364
Charlton, M., Gane, E. J., Manns, M. P., Brown, R. S., Curry, M. P., Kwo, P. Y., Fontana, R. J., Gilroy, R. K., Teperman, L. W., Muir, A. J., et al. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.10.001 · Cited by 347
Manns, M., Pol, S., Jacobson, I. M., Marcellin, P., Gordon, S. C., Peng, C.-Y., Chang, T.-T., Everson, G. T., Heo, J., Gerken, G., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61059-x · Cited by 342
Durand, C. M., Bowring, M. G., Brown, D. M., Chattergoon, M. A., Massaccesi, G., Bair, N., Wesson, R., Reyad, A., Naqvi, F. F., Ostrander, D., et al. (2018) · Annals of Internal Medicine · doi:10.7326/m17-2871 · Cited by 302
Forns, X., Charlton, M., Denning, J., McHutchison, J. G., Symonds, W. T., Brainard, D., Brandt‐Sarif, T., Chang, P., Kivett, V., Castells, L., et al. (2015) · Hepatology · doi:10.1002/hep.27681 · Cited by 229
OPTN/SRTR 2016 annual data report: lung
Valapour, M., Lehr, C. J., Skeans, M. A., Smith, J. M., Carrico, R., Uccellini, K., Lehman, R., Robinson, A., Israni, A. K., Snyder, J. J., et al. (2018) · American Journal of Transplantation · doi:10.1111/ajt.14562 · Cited by 163
Hepatitis C Virus Seropositivity in Organ Donors and Survival in Heart Transplant Recipients
Gasink, L. B., Blumberg, E. A., Localio, A. R., Desai, S. S., Israni, A. K., & Lautenbach, E. (2006) · JAMA · doi:10.1001/jama.296.15.1843 · Cited by 159
The Future Direction of the Adult Heart Allocation System in the United States
Meyer, D. M., Rogers, J. G., Edwards, L., Callahan, E. R., Webber, S. A., Johnson, M. R., Vega, J. D., Zucker, M. J., & Cleveland, J. C. (2014) · American Journal of Transplantation · doi:10.1111/ajt.13030 · Cited by 146
Self-citationProper inference from Simon's two‐stage designs
Koyama, T., & Chen, H. (2007) · Statistics in Medicine · doi:10.1002/sim.3123 · Cited by 143
Haji, S. A., Starling, R. C., Avery, R. K., Mawhorter, S. D., Tuzcu, E. M., Schoenhagen, P., COOK, D. J., Ratliff, N. B., McCarthy, P. M., Young, J. B., et al. (2004) · The Journal of Heart and Lung Transplantation · doi:10.1016/s1053-2498(03)00148-7 · Cited by 142
Leroy, V., Dumortier, J., Coilly, A., Sebagh, M., Fougerou‐Leurent, C., Radenne, S., Botta, D., Durand, F., Silvain, C., Lebray, P., et al. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2015.05.030 · Cited by 134
On the estimation of the binomial probability in multistage clinical trials
Jung, S., & Kim, K. M. (2004) · Statistics in Medicine · doi:10.1002/sim.1653 · Cited by 107
Continuous Toxicity Monitoring in Phase II Trials in Oncology
Ivanova, A., Qaqish, B. F., & Schell, M. J. (2005) · Biometrics · doi:10.1111/j.1541-0420.2005.00311.x · Cited by 96
The Drug-Intoxication Epidemic and Solid-Organ Transplantation
Mehra, M. R., Jarcho, J. A., Cherikh, W. S., Vaduganathan, M., Lehman, R. R., Smits, J. M., & Stehlik, J. (2018) · New England Journal of Medicine · doi:10.1056/nejmc1802706 · Cited by 82
Self-citationPerioperative Ledipasvir–Sofosbuvir for HCV in Liver-Transplant Recipients
Levitsky, J., Verna, E. C., O’Leary, J. G., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmc1611829 · Cited by 80
Chronic Viral Hepatitis: Current Management and Future Directions
Do, A., & Reau, N. S. (2020) · Hepatology Communications · doi:10.1002/hep4.1480 · Cited by 41
Woolley, A. E., Piechura, L. M., Goldberg, H. J., Singh, S. K., Coppolino, A., Baden, L. R., & Mallidi, H. R. (2020) · Annals of Cardiothoracic Surgery · doi:10.21037/acs.2020.01.03 · Cited by 16
Self-citationWhat’s Hot in Clinical Infectious Diseases? 2019 IDWeek Summary
Moss, S., & Boucher, H. W. (2020) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaa104 · Cited by 6
Cited by
EASL recommendations on treatment of hepatitis C: Final update of the series☆
Pawlotsky, J.-M., Negro, F., Aghemo, A., Berenguer, M., Dalgard, O., Dusheiko, G., Marra, F., Puoti, M., & Wedemeyer, H. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.08.018 · Cited by 1,252
Ghany, M. G., Morgan, T. R., & Panel, A. H. C. G. (2020) · Hepatology · doi:10.1002/hep.31060 · Cited by 955
Velleca, A., Shullo, M. A., Dhital, K., Azeka, E., Colvin, M., DePasquale, E., Farrero, M., García-Guereta, L., Jamero, G., Khush, K., et al. (2023) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2022.10.015 · Cited by 645
Spearman, C. W., Dusheiko, G. M., Hellard, M., & Sonderup, M. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32320-7 · Cited by 404
Bhattacharya, D., Aronsohn, A., Price, J., Lo Re, V., the American Association for the Study of Liver Diseases–Infectious Diseases Society of America HCV Guidance Panel, Heald, J., Demisashi, G., Durzy, E., Davis-Owino, A., & Tynes, S. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciad319 · Cited by 296
Metadata
- Authors
- Woolley, A. E., Singh, S. K., Goldberg, H. J., Mallidi, H. R., Givertz, M. M., Mehra, M. R., Coppolino, A., Kusztos, A. E., Johnson, M. E., Chen, K., Haddad, E. A., Fanikos, J., Harrington, D. P., Camp, P. C., & Baden, L. R.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-04-25
- Volume
- 380
- Issue
- 17
- Pages
- 1606-1617
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2926358141
- Cited by
- 335
- References
- 28
- FWCI
- 30.50
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.